Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
SHA: 600380
Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...
Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...
Joincare’s Generic Seretide Accepted for NMPA Review
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...
Joincare’s Biosimilar Tocilizumab Approved for Marketing in China
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...
Joincare Pharmaceutical Plans USD 300-400 Million GDR Issue for Global Expansion
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to issue Global Depository...